Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model.
about
Autoimmune responses in T1DM: quantitative methods to understand onset, progression, and prevention of diseaseCoherent somatic mutation in autoimmune disease.The use of mouse models to better understand mechanisms of autoimmunity and toleranceTRAIL-expressing CD8+ T cells mediate tolerance following soluble peptide-induced peripheral T cell deletion.Biological and clinical developments in melanoma vaccines."Viral déjà vu" elicits organ-specific immune disease independent of reactivity to self.Antigen-specific immunotherapy: is it a real possibility to combat T-cell-mediated autoimmunity?Specific T-cell tolerance may be preceded by a primary response.In situ induction of dendritic cell-based T cell tolerance in humanized mice and nonhuman primates.Acute and chronic animal models for the evaluation of anti-diabetic agents.Cell-free tumor antigen peptide-based cancer vaccinesT cell priming versus T cell tolerance induced by synthetic peptides.Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance.Molecular basis for checkpoints in the CD8 T cell response: tolerance versus activation.Oral insulin treatment suppresses virus-induced antigen-specific destruction of beta cells and prevents autoimmune diabetes in transgenic mice.Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction.Engineered erythrocytes covalently linked to antigenic peptides can protect against autoimmune disease.Viruses and cytotoxic T lymphocytes in type 1 diabetes.Immunological perspective of self versus tumor antigens: insights from the RIP-gp model.Peptide-MHC-based nanovaccines for the treatment of autoimmunity: a "one size fits all" approach?Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapyCTL induction by cross-priming is restricted to immunodominant epitopes.Prevention of diabetes by manipulation of anti-IGRP autoimmunity: high efficiency of a low-affinity peptide.Autoantigen-induced deletion of peripheral self-reactive T cells.Peptide immunization restimulates the memory CD4 T cell response but fails to induce cytotoxic T lymphocytes in cynomolgus monkeys.Glycogen Synthase Kinase-3 Modulates Cbl-b and Constrains T Cell Activation.Quantifying the importance of pMHC valency, total pMHC dose and frequency on nanoparticle therapeutic efficacy.Ag and IL-2 immune complexes efficiently expand Ag-specific Treg cells that migrate in response to chemokines and reduce localized immune responses.Experimental myositis inducible with transfer of dendritic cells presenting a skeletal muscle C protein-derived CD8 epitope peptide.The Major Histocompatibility ComplexCD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy
P2860
Q33729769-346BDC64-3D74-450A-AEFE-39A774CB59B6Q33837769-FE0496F4-925D-4DA3-BDCC-0A1BF7C6E333Q34208888-6724D2BF-4115-4680-A382-AA4D5FD4BC4CQ34378771-93C3C8B8-4AC7-45B8-A0EE-9633015AFE7DQ34452007-0AA3CFD7-045A-4027-B587-F98178586875Q34520218-1AE4B66E-3DFA-4D80-9D6A-75D225C45D65Q34975264-E067C65E-AFF2-4C26-8D76-9122A57A777EQ35507250-77D75DE5-B42E-4385-B715-2A975F429D51Q35669101-317F7127-185E-48C6-B0F6-7D6878B1A956Q35777139-5D6220BE-7C3C-4208-9DEF-32F1F005FC16Q36084122-8694F28B-2D63-4AC9-83E4-8CC3209F2DA4Q36365135-25E0E749-A702-4D66-A374-F9E84F41C8FDQ36369913-48C8B4E6-4F95-463A-BE49-9B0181E7811BQ36768858-FC3CEB00-8ACE-43F5-939F-3E38D0C3EE30Q37359669-99989995-5345-4D5C-A712-4DF675E83D08Q37445352-92BF81C9-3539-4E29-8E19-754F1AB830F9Q37730171-4BEF0155-D83E-4243-B2DD-31EB505F2AA4Q37823420-70124A27-5186-4AC4-A5F6-AEE12EDA7F20Q37864698-876F9956-2012-49B1-A126-496DEB20059BQ37866131-72945704-B84D-4985-81E2-FA7CDAD89B04Q39782156-DAE98045-2688-4804-AD37-6FC2CB39E107Q39888117-F2500DC4-3EBB-4DCF-AAC5-B5A7BED6D0C5Q40418904-DCD0575E-1B41-489C-937F-B31964172480Q41098064-91833A5C-E79F-4846-9ED6-536B8496D2F0Q46596868-C2DB75C1-8BC1-47C1-8600-5FD475CF868EQ47434293-0A08E287-A121-44D2-992C-6BB67E22A263Q50908015-A857EB84-5876-4533-89AB-45821999695BQ53078255-27BD7C80-0C39-49B3-8D03-A1B8D56CF9DBQ53647622-EB120DE3-E7E2-410D-B0B7-635E4365D764Q57159149-B3796B40-DCD9-4210-90D2-6CECF9965FF6Q58235013-9A003659-7C33-4677-809B-A2F3E3CB3B8E
P2860
Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model.
description
1994 nî lūn-bûn
@nan
1994 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Peptide-induced T-cell toleran ...... s in a transgenic mouse model.
@ast
Peptide-induced T-cell toleran ...... s in a transgenic mouse model.
@en
Peptide-induced T-cell toleran ...... s in a transgenic mouse model.
@nl
type
label
Peptide-induced T-cell toleran ...... s in a transgenic mouse model.
@ast
Peptide-induced T-cell toleran ...... s in a transgenic mouse model.
@en
Peptide-induced T-cell toleran ...... s in a transgenic mouse model.
@nl
prefLabel
Peptide-induced T-cell toleran ...... s in a transgenic mouse model.
@ast
Peptide-induced T-cell toleran ...... s in a transgenic mouse model.
@en
Peptide-induced T-cell toleran ...... s in a transgenic mouse model.
@nl
P2093
P2860
P356
P1476
Peptide-induced T-cell toleran ...... s in a transgenic mouse model.
@en
P2093
Hengartner H
Odermatt B
Zinkernagel RM
P2860
P304
P356
10.1073/PNAS.91.2.444
P407
P577
1994-01-01T00:00:00Z